AngioDynamics CEO Highlights Debt-Free Turnaround and Growth in MedTech Segment
AngioDynamics CEO Jim Clemmer outlined the company's debt-free transformation and growth in its MedTech segment during the Needham Healthcare Conference. The company has achieved a 25% CAGR in its MedTech segment, with the Auryon laser gaining market share and NanoKnife receiving FDA clearance. The company's balance sheet is strong, with significant cash reserves.
Tickers: $ANGO
Topics: AngioDynamics AngioVac Auryon debt-free FDA clearance financial strategy market share MedTech NanoKnife